Table of contents

Electronic pages

• Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ (25 September, 2020)

  Meredith J Ventura, Emmanuel Guajardo, Eva H Clark, Kalpana Bhairavarasu, Riyad Y Kherallah, Andrew R DiNardo, Xunyan Ye, Pedro A Piedra, Robert L Atmar, Sandeep K Agarwal
• Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Ventura et al’

  (20 November, 2020)

  Juliette Chommeloux, Marie Pouletty, Naim Ouldali, Mathieu Kerneis, Alexis Mathian, Raphaele Mestiri, Julien Rohmer, Guillaume Hekimian, Isabelle Melki
• Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ (1 October, 2020)

  Florence Jeny, Raphael Lhote, Gwenael Lorillon, Nicolas Belhomme, Grégory Pugnet, Raphaël Borie, Aurélien Justet, Stephane Jouneau, Nathalie Freymond, Arsène Mekinian, Robin Dhote, Yacine Tandjaoui-Lambiotte, Nathalie Saindenberg, Pierre Gazengel, Baptiste Hervier, Julien Haroche, Alexis Mathian, Miguel Hié, Thibaud Chazal, Dov Taieb, Yurdagul Uzunhan, Jérôme Le Pavec, Isabella Annesi-Maesano, Emmanuel Bergot, Abdellatif Tazi, Zahir Amoura, Dominique Valeyre, Hilario Nunes, Fleur Cohen-Aubart
• Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al

  (1 October, 2020)

  Andrea Hermina Györfi, Georg Schett, Jörg H W Distler
• Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’ (25 September, 2020)

  Bo-Yao Wu, Chi-Ho Chan, James Cheng-Chung Wei
• Response to: ‘Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’’ by Wu et al

  (25 September, 2020)

  Jose L Pablos, María Galindo, Ricardo Blanco, José M Alvaro-Gracia
• No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) (7 August, 2020)

  Peer Aries, Christof Iking-Konert
• Correspondence on ‘Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis’ (6 October, 2020) Free

  Chuanhui Xu
• Response to: ‘Correspondence on ‘Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis’’ by Xu (6 October, 2020) Free

  Chi Chiu Mok
• Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’ (1 October, 2020) Free

  Zhuochao Zhou, Fan Wang, Yue Sun, Jialin Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Yijun You, Chengde Yang, Junna Ye
• Response to: ‘Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’ by Zhou et al

  (1 October, 2020) Free

  Maria G Tektonidou, Angela Tincani, Michael M Ward
• Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’ (6 October, 2020) Free

  Markus Bredemeier
• Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier (6 October, 2020) Free

  James R Seibold, Veronika Kohlbrenner, Margarida Alves, Oliver Distler
• Correspondence on ‘Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence’ (1 October, 2020) Free

  Zheng-Liang Zhang, Wei Huang, Guo-Hua Lv, Jing Li, Ming-Xiang Zou, Zhi-Hui Dai
• Response to ‘Correspondence on “Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence” by Zhang et al

  (1 October, 2020) Free

  Bon San Koo, Ji Seon Oh, Seo Young park, Ji Hui Shin, Ga Young Ahn, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim
• Correspondence to ‘Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression’ (6 October, 2020) Free

  Li-Tzu Wang, Kevin Sheng-Kai Ma
• Response to: ‘Correspondence to ‘Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression’’ by Wang and Ma (6 October, 2020) Free

  Abdulla Watad, Charlie Bridgewood, Dennis G McGonagle
• Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’ (28 September, 2020) Free

  Hasan Satış, Ergin Aydemir, Kerem İzmirlioğlu, Abdurrahman Tufan
• Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al

  (28 September, 2020) Free

  Seza Ozen, Fabrizio De Benedetti
• Correspondence on ‘Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells’ (22 September, 2020) Free

  Honglin Wang, Lei Niu
• Response to ‘Correspondence on ‘Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells’’ by Wang and Niu (22 September, 2020) Free

  Pei He, Hong Zhu, Long-Fei Wu, Fei-Yan Deng, Shu-Feng Lei
• Role of interaction between B cells and epithelial cells in pSS (15 October, 2020) Free

  Sarah Pringle, Gwenny M Verstappen, Hendrika Bootsma, Frans G M Kroese
• Response to: ‘Role of interaction between B cells and epithelial cells in pSS’ by Pringle et al

  (15 October, 2020) Free

  Elodie Rivière, Xavier Mariette, Gaetane Nocturne
• Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases (7 August, 2020) Free

  Ryu Watanabe, Motomu Hashimoto
• Management of immune checkpoint inhibitor-induced polymyalgia rheumatica (4 September, 2020) Free

  Kornelis S M van der Geest, Maria Sandovici, Abraham Rutgers, T Jeroen N Hiltermann, Sjoukje F Oosting, Riemer H J A Slart, Elisabeth Brouwer